Current treatment algorithms encourage polypharmacy when initial treatments with a single drug are not effective. While there is some increased response, polypharmacy only increases the side effects burden and can result in untoward drug/drug interactions. These types of problems do not occur with CES.
Many psychotropic medications for the treatments of depression, anxiety and insomnia have discontinuation syndromes. Given the high rate of discontinuation of these medications by patients due to side effects and lack of efficacy, many patients unfortunately suffer when the take a medication prescribed to alleviate their suffering. This does not occur with CES. There are circumstances, for example prior to surgery, when certain psychotropic medications are required to be discontinued. CES does not have to be discontinued prior to surgery.
One of the greatest concerns in treating patients with depression, anxiety and insomnia involves suicide. We know there is an increased risk of suicide in depressed patients but often global insomnia is under appreciated as a significant risk factor for suicide as well. Although safer than the older tricyclic and tetracylcic antidepressants, the current medications carry a significant risk of death in overdose, especially when combined with other analgesic medications. Too often, the medications we prescribed to prevent suicide become a means through which the patient attempts suicide. In addition, there are black box warnings that these medications may increase suicidal impulses, especially in adolescents. CES does not pose this risk.
Excerpts from “A View from the Trenches” written by Jason Worchel, M.D.
More CES Research – https://www.cesultra.com/research-resources/